• 老师“成本”太高 日本小学用机器人教英语 2019-07-08
  • “奋斗了就有答案” 江西宁都县曾北方带领残障人士创业 2019-07-08
  • 萌文章中国国家地理网 2019-07-04
  • 港媒热议“一地两检”通过:中国香港即将开启高铁时代 2019-06-20
  • 首部宣传“一带一路”的故事片《路遥归梦》开拍在即 2019-06-09
  • 台风缘何此时频频光顾 2019-06-09
  • 看着就想笑这一贴证明,计划经济不是来自苏联,而是来自资本主义 2019-06-08
  • 当好新时代国资国企改革排头兵 2019-06-08
  • 脑乱发傻话啦?我是嘛? 2019-06-07
  • 女性之声——全国妇联 2019-06-06
  • 林志玲现身机场穿粉色上衣变活力少女 2019-06-05
  • 我还得感谢你给咱升级呢! 2019-06-05
  • 电动汽车消费仍需摆脱“里程焦虑” 2019-06-04
  • 【人事】中共临汾市委组织部公示3名拟任职干部 2019-06-03
  • 绍兴印染布质量比对成果发布 部分指标国际领先 2019-06-02
  • 扫一扫有惊喜

    荷兰Mucosis B.V.公司

    当前位置:

    荷兰Mucosis B.V.公司

    加拿大快乐8开奖数据 www.rkgxy.tw 发布日期:2015-09-25 11:09:07   信息来源:原创   点击量:5116



    Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM®, an intranasal vaccine to prevent respiratory syncytial virus infection. Our vaccines are based on the patented and validatedMimopath® technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in our proof-of-concept animal and human studies of our FluGEM® vaccine candidate.


    The Mucosis Mimopath® technology is a plug- and play vaccine platform that addresses the innate immune system through Toll-like receptor 2 (TLR2) to activate the adaptive immune system. This mechanism efficiently evokes immune responses that engage disease-causing pathogens at their port of entry, the mucosal layers of the body. Uniquely, our technology is built on particles that not only elicit a strong and robust systemic immune response, but also a strong local immune response in mucosal layers in the nose, airways, gut and other places in the body.


    The core of the Mimopath® technology is the Bacterium-Like Particle (BLP). The BLPs are safe and derived from food-grade bacteria. There are two modes of application of the BLPs. The first is an Add & Mix approach in which the immune stimulating properties of the BLPs are used to improve existing vaccines and to enable a mucosal route of administration. The second is a Bound approach in which the BLPs not only act as immunostimulant but also as a carrier for the subunit antigen(s). The binding of the antigens is achieved by a linker domain called Protanthat binds to the surface of the BLPs.


    Mimopath®-based vaccines were used by our scientists and collaborators who demonstrated in animal models that Mimopath®-based vaccines are protective against live parasites (malaria) viruses (influenza, hepatitis B) and bacteria (Streptococcus pneumonia, Yersinia pestis). Mimopath®-based vaccines were shown to be effective both as injectable and mucosal formats and in addition, proved to be highly effective in stimulation of the neonatal immune system. This forms the basis for a broad application of this new and innovative vaccine technology.




    Ramirez K , Ditamo Y, Rodriguez L, Picking WL, Roosmalen ML van, Leenhouts K, Pasetti MF. Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection. Mucosal Immunol. 2010; 3:159–171.

  • 老师“成本”太高 日本小学用机器人教英语 2019-07-08
  • “奋斗了就有答案” 江西宁都县曾北方带领残障人士创业 2019-07-08
  • 萌文章中国国家地理网 2019-07-04
  • 港媒热议“一地两检”通过:中国香港即将开启高铁时代 2019-06-20
  • 首部宣传“一带一路”的故事片《路遥归梦》开拍在即 2019-06-09
  • 台风缘何此时频频光顾 2019-06-09
  • 看着就想笑这一贴证明,计划经济不是来自苏联,而是来自资本主义 2019-06-08
  • 当好新时代国资国企改革排头兵 2019-06-08
  • 脑乱发傻话啦?我是嘛? 2019-06-07
  • 女性之声——全国妇联 2019-06-06
  • 林志玲现身机场穿粉色上衣变活力少女 2019-06-05
  • 我还得感谢你给咱升级呢! 2019-06-05
  • 电动汽车消费仍需摆脱“里程焦虑” 2019-06-04
  • 【人事】中共临汾市委组织部公示3名拟任职干部 2019-06-03
  • 绍兴印染布质量比对成果发布 部分指标国际领先 2019-06-02
  • 上海福利彩票平台 变形金刚APP 广西快乐十分历史记录 安徽11选5开奖结果爱彩乐 地府烈焰免费试玩 游戏厅捕鱼达人攻略 门兴格拉德巴赫 欧冠皇马vs曼城 东方6+1开奖号 大草原现金游戏